Results 1 to 10 of about 15,436 (169)

Prevalence and Characteristics of Transthyretin Amyloid Cardiomyopathy in Hypertrophic Cardiomyopathy

ESC Heart Failure
Aims Recognition of transthyretin amyloid cardiomyopathy is increasing due to advances in cardiac imaging and diagnostic strategies, but questions remain regarding disease frequency and characteristics.
Francesco Cappelli, Pablo Garcia-Pavia, Thibaud Damy   +2 more
exaly   +7 more sources

3 Discordant Extracardiac Amyloid Proteins Highlighting Bystander Deposition in a Case of Light-Chain Amyloid Cardiomyopathy [PDF]

JACC: Case Reports
Background: Accurate differentiation of immunoglobulin light-chain (AL) from transthyretin (ATTR) amyloid cardiomyopathy is critical, as misclassification may delay appropriate therapy and worsen outcomes.
Roxanne Coderre, MD, Gregorio Tersalvi, MD, Rosalyn O. Adigun, MD, Barry A. Boilson, MD, Daniel D. Borgeson, MD, Alfredo L. Clavell, MD, Ian C. Chang, MD, Nadine H. Abdallah, MD, Martha Grogan, MD, Omar F. AbouEzzeddine, MDCM, MS   +9 more
doaj   +2 more sources

Coexistence of Hypertrophic Cardiomyopathy and Hereditary Transthyretin Amyloid Cardiomyopathy [PDF]

JACC: Case Reports
Background: Left ventricular wall thickening may result from disease such as hypertrophic cardiomyopathy (HCM) or infiltrative cardiomyopathies such as transthyretin amyloidosis (ATTR).
Roxanne Coderre, MD, Gregorio Tersalvi, MD, Rosalyn O. Adigun, MD, Barry A. Boilson, MD, Daniel D. Borgeson, MD, Alfredo L. Clavell, MD, Ian C. Chang, MD, Angela Dispenzieri, MD, Martha Grogan, MD, Omar F. AbouEzzeddine, MDCM, MS   +9 more
doaj   +2 more sources

Machine Learning of Echocardiographic Left Ventricular Myocardial Radiomics for Identification of Transthyretin Amyloid Cardiomyopathy [PDF]

JACC: Advances
Background: Transthyretin amyloid cardiomyopathy (ATTR-CM) is an important cause of heart failure (HF) with increased left ventricular (LV) wall thickness that can be challenging to distinguish from other LV hypertrophic processes.
Ali A. Elzieny, MD, MSc, Rabah Alreshq, MD, Ikram Ullah, MD, Denise Fine, BS, Sergio Teruya, MD, MS, Stephen Helmke, MPH, RDCS, Cesia Gallegos, MD, MHS, Edward J. Miller, MD, PhD, Jeremy A. Slivnick, MD, Mathew S. Maurer, MD, Baojun Li, PhD, Frederick L. Ruberg, MD   +11 more
doaj   +2 more sources

Diagnostic Trends and Geographic Health Care Disparities Among Patients With Transthyretin Amyloid Cardiomyopathy [PDF]

Journal of the American Heart Association: Cardiovascular and Cerebrovascular Disease
Background Transthyretin amyloid cardiomyopathy (ATTR‐CM) is a rare, life‐threatening form of restrictive cardiomyopathy. Access to cardiology providers and specialized amyloid centers may impact ATTR‐CM diagnosis.
Joshua D. Mitchell, Kevin M. Alexander, Hanh Dung Dao, Elizabeth Nagelhout, Neil Lamarre, Margarita Udall, Richard K. Cheng   +6 more
doaj   +2 more sources

Systemic Oxalosis Mimicking Transthyretin Amyloid Cardiomyopathy [PDF]

JACC: Case Reports
Background: Technetium-99m pyrophosphate (Tc-99m PYP) scintigraphy is a noninvasive imaging modality in the diagnosis of transthyretin amyloid cardiomyopathy (ATTR-CM), though false positive results may result in adverse clinical outcomes.
Bhavya Ancha, MD, Virginia Hahn, MD, Charles Steenbergen, Jr., MD, PhD, Cheng-Ying Ho, MD, PhD, Ahmad Kohsar, DO, Emily Brown, MGC, CGC, Mark Ranek, PhD, Claire Brookmeyer, MD, Michael Polydefkis, MD, Joban Vaishnav, MD   +9 more
doaj   +2 more sources

Pathogenic Characterization of a Novel G47R Transthyretin Mutation in Early‐Onset Amyloid Cardiomyopathy [PDF]

Journal of the American Heart Association: Cardiovascular and Cerebrovascular Disease
Background Transthyretin amyloid cardiomyopathy is a progressive infiltrative cardiomyopathy driven by the deposition of amyloid fibrils derived from destabilized transthyretin (TTR).
Bo Wang, Rui Gao, Xinyue Cui, Mengdie Wang, Jialu Sun, Di Shen, Yajing Wang, Jianli Zhao, Ruifang Zhang, Li Zhang, ZhiYu Liu, Xuejing Duan, Li Li, Yu Liu, Jinying Zhang, Junnan Tang   +15 more
doaj   +2 more sources

AL-amyloidosis with cardiac involvement. Diagnostic capabilities of non-invasive methods

Терапевтический архив, 2021
There are presented the literature data and a description of the clinical course of the disease in isolated/predominant cardiac amyloidosis. Amyloid cardiomyopathy is the most common phenocopy of hypertrophic cardiomyopathy.
Alexandra Ya. Gudkova, Sergei V. Lapekin, Tinatin G. Bezhanishvili, Maria A. Trukshina, Victoria G. Davydova, Aleksandr N. Krutikov, Aleksandr N. Kulikov, Anna A. Streltsova, Sofiia E. Andreeva, Roman V. Grozov, Anzhelika A. Poliakova, Anna A. Kostareva, Galina N. Salogub, Evgenii V. Shlyakhto   +13 more
doaj   +1 more source

A machine learning model for identifying patients at risk for wild-type transthyretin amyloid cardiomyopathy

Nature Communications, 2021
Transthyretin amyloid cardiomyopathy is a treatable but often unrecognized cause of heart failure. We derived and validated a machine learning model based on medical diagnostic codes that identifies heart failure patients at risk for wild-type ...
Ahsan Huda, Adam Castaño, Anindita Niyogi, Jennifer Schumacher, Michelle Stewart, Marianna Bruno, Mo Hu, Faraz S. Ahmad, Rahul C. Deo, Sanjiv J. Shah   +9 more
doaj   +1 more source

A new era in treatment of cardiac amyloidosis: an overview of the Congress of cardiology

Лечащий Врач, 2022
Amyloidosis is a group of diseases characterized  by accumulation of a protein of a specific fibrillar structure in the interstitium of various organs and tissues.
I. E. Strelkova
doaj   +1 more source